paricalcitol: Clinical Trials

10 trials of paricalcitol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated. 10 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 110Completed 6, Terminated 4

Follow paricalcitol: new trials by email Literature Review of paricalcitol trials Research Report on paricalcitol

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
5-FU, Leucovorin, Liposomal Irinotecan - Pancreatic Cancer, Pancreas Cancer
Phase 1CompletedWashington University School of Medicine202019-07-112022-10-05
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Gemcitabine, Nab-paclitaxel, Paricalcitol - Pancreatic Cancer
Phase 1TerminatedDana-Farber Cancer Institute362018-12-052025-03-21
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
Paricalcitol - Pancreatic Cancer
Phase 1TerminatedAbramson Cancer Center at Penn Medicine32017-09-282022-03-31
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nab-paclitaxel - Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7
Phase 1CompletedM.D. Anderson Cancer Center92017-02-202023-02-09
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Paricalcitol, Abraxane, Gemcitabine - Adenocarcinoma of the Pancreas
Phase 1CompletedAbramson Cancer Center at Penn Medicine152014-01-012025-07-25
Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions
Paricalcitol Capsules, 4 mcg - Healthy
Phase 1CompletedDr. Reddy's Laboratories Limited692010-11-012014-12-23
Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery
paricalcitol, radiation therapy, laboratory biomarker analysis - Mucinous Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
Phase 1TerminatedWake Forest University Health Sciences22010-08-012018-07-02
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
docetaxel, ixabepilone, paclitaxel - Breast Cancer
Phase 1CompletedWake Forest University Health Sciences242008-03-012017-05-30
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
paricalcitol, zoledronic acid - Multiple Myeloma and Plasma Cell Neoplasm
Phase 1TerminatedRoswell Park Cancer Institute72005-08-012013-02-01
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
gemcitabine hydrochloride, paricalcitol - Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedRoswell Park Cancer Institute342004-08-012014-12-09

Conditions studied

Pancreatic Neoplasms (3)  ·  Breast Neoplasms (1)  ·  Multiple Myeloma (1)  ·  Neoplasms, Plasma Cell (1)  ·  Rectal Neoplasms (1)

Sponsors

Abramson Cancer Center at Penn Medicine (2)  ·  Roswell Park Cancer Institute (2)  ·  Wake Forest University Health Sciences (2)  ·  Dana-Farber Cancer Institute (1)  ·  Dr. Reddy's Laboratories Limited (1)  ·  M.D. Anderson Cancer Center (1)  ·  Washington University School of Medicine (1)

Countries

United States (9)  ·  India (1)

Top investigators

Peter O'Dwyer, MD (2)  ·  Asher A. Chanan-Khan, MD (1)  ·  Brandon G Smaglo, MD (1)  ·  Dr. Pankaj Kumar Jha, MD (1)  ·  George Yacoub, MD (1)  ·  Julia A. Lawrence (1)  ·  Kian-Huat Lim, M.D, Ph.D. (1)  ·  Kimberly Perez, MD (1)  ·  Renuka Iyer, MD (1)  ·  Susan A. Melin, MD (1)

Results publications

PMID 42185478

NIH funding

P30CA012197 (1)